CSL FY25 Results and Major Strategic Initiatives
Filed with ASX · · 7 pages · English
Earlier from CSL
- CSL Results Presentation
- CSL Statutory Accounts for FY2025
- Health Canada Has Authorized CSL's ANDEMBRY(R) (garadacimab) as Once-Monthly Treatment for Hereditary Angioedema (HAE)
- Health Canada Has Authorized CSL's ANDEMBRY® (garadacimab) as Once-Monthly Treatment for Hereditary Angioedema (HAE)
- U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start
Later from CSL
- CSL partners on new coagulation treatment
- VarmX Partners With CSL in a Strategic Collaboration and Option Agreement to Develop Novel Investigational Coagulation Treatment
- CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
- CSL Behring Signs Letter of Intent with pan-Canadian Pharmaceutical Alliance (pCPA) for Public Reimbursement of HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B
- CSL near-term emissions reduction targets validated by the SBTi
Follow CSL into a list and get an email when it puts out news.
Follow CSL